title: [Preliminary clinical evaluations of panipenem-betamipron in the treatment of hematological malignancy infections].
abstract: OBJECTIVE
  To evaluate the clinical efficacy and safety of intravenous panipenem-betamipron in the treatment of hematological malignancies infections.
  
  
  METHODS
  From October 2009 to December 2010, a total of 286 hematological malignancy infection patients were recruited into this open-label, perspective and multicenter clinical trial to receive an intravenous daily dose panipenem-betamipron of 0.5 g every 6 or 8 hours for 7 - 14 days. All clinical change and adverse reactions were recorded.
  
  
  RESULTS
  The total effective rate of panipenem-betamipron in the treatment of hematological malignancy infections was 86.6% (206/238). The effective rates of septicemia, pulmonary infections, urinary tract infections, digestive canal infections, oral infections and other infections were 68.2% (15/22), 89.3% (100/112), 77.8% (14/18), 100% (22/22), 83.3% (10/12) and 86.5% (45/52) respectively. The overall bacterial eradication rate was 85.07% (57/67) and the rate of adverse reactions 5.9% (17/286).
  
  
  CONCLUSIONS
  Panipenem-betamipron is both safe and effective in the treatment of hematological malignancy infections.
authors.affiliation: West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Yong-Qian
authors.initials: YQ
authors.lastname: Jia
authors.forename: Xu
authors.initials: X
authors.lastname: Cui
authors.forename: Jie
authors.initials: J
authors.lastname: Huang
authors.forename: Chuan
authors.initials: C
authors.lastname: He
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013845:Thienamycins / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D013845:Thienamycins; D015091:beta-Alanine; C075316:panipenem-betamipron